Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, ACC

Hansa Biopharma announces participation in Fall conferences and an updated financial calendar

LUND, Sweden, Aug. 31, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will present at the following upcoming investor conferences in September:           

A link to the presentations and webcasts will be available on the Events & Presentations page of the Company's website at http://www.hansabiopharma.com.


Aug 31,2020    Kempen Road Show, Tel Aviv/Paris/Benelux (virtual)
Sep 3, 2020     Pareto Healthcare Conference, Stockholm (virtual)
Sep 9, 2020     Citibank's Annual BioPharma Virtual Conference, Boston (virtual)
Sep 15, 2020   H.C. Wainwright Healthcare Conference, NYC (virtual)
Sep 16, 2020   Bank of America Merill Lynch Healthcare Conf., London (virtual)
Sep 18, 2020   MorganStanley Global Healthcare Conference, NYC (virtual)
Sep 23, 2020   ABG Small & Mid Cap Seminar, Copenhagen and virtual
Oct 22, 2020   Interim Report Jan-Sep 2020
Oct 29, 2020   Hansa Biopharma Capital Markets Day, Copenhagen and virtual
Nov 17, 2020   Bryan Garnier Healthcare Conference, Paris
Nov 18, 2020   Jefferies Healthcare Conference, London
Nov 25, 2020   Ökonomisk Ugebrev Life Science Conference, Copenhagen
Feb 2, 2021     Interim report for Jan - Dec 2020
April 8, 2021    Annual Report 2020
April 22, 2021   Interim report for Jan - Mar 2021
July 15, 2021    Interim report for Jan - Jun 2021
Oct 21, 2021    Interim report for Jan - Sep 2021


For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com  

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

This information was brought to you by Cision http://news.cision.com


The following files are available for download:




SOURCE Hansa Biopharma AB

These press releases may also interest you

at 16:05
Seagen Inc. today reported financial results for the third quarter and nine months ended September 30, 2020. The Company also highlighted ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv) and TUKYSA® (tucatinib) commercial and...

at 16:05
Cerus Corporation today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include: Q3 2020 Total Revenue of $29.2 million - driven by significant year-over-year platelet kit sales...

at 16:05
Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release third quarter 2020 financial results after the market...

at 16:05
Vertex Pharmaceuticals Incorporated today reported consolidated financial results for the third quarter ended September 30, 2020 and revised upward its full-year 2020 financial guidance for product revenues. "This has been another very strong...

at 16:04
Firelands Scientific a leading medical cannabis company announced that it has earned certification as a B Corporation. As a cutting-edge medical cannabis company that is devoted to providing patients with the highest quality, natural sun grown...

at 16:02
NuVasive, Inc. , the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2020....

News published on 31 august 2020 at 02:12 and distributed by: